FWA
NVAX icon

Flagship Wealth Advisors’s Novavax NVAX Stock Holding History

Flagship Wealth Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$942 Buy
+100
New +$896 ﹤0.01% 473

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Flagship Wealth Advisors's NVAX Position: Q2 2026 in Review

Flagship Wealth Advisors opened a new position in Novavax (NVAX) in Q2 2026: 100 shares worth $942. The stake represents ﹤0.01% of the portfolio and ranks #473 among its holdings.

265 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Flagship Wealth Advisors held 100 shares of Novavax worth $942 as of Q2 2026.
  • Novavax was a new Flagship Wealth Advisors position in Q2 2026.
  • Novavax made up ﹤0.01% of Flagship Wealth Advisors's portfolio in Q2 2026, its #473 holding.
  • 265 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Flagship Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.